Definitive Contract 75N93022C00004
Award Date 1/10/22
Potential Completion Date 1/9/24
Potential Value $598K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98102, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $444,428 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of a Leishmania vaccine, combining parasite and vector components. This contract was designated as a total small business set-aside. PAI Life Sciences has a history of securing federal contracts and grants, particularly from NIAID, for the development of vaccines and...
- This $441,905 firm fixed-price definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, to PAI Life Sciences Inc. for the development of a prophylactic onchocerciasis (river blindness) vaccine. The contract is designated as a total small business set-aside. PAI Life Sciences, a small disadvantaged business, will collaborate with Thomas Jefferson University and New York Blood...
- This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases to Teichos Laboratories, LLC, a small business located in West Lafayette, IN. The $300,000 firm fixed price contract is for research on a novel TLR2 agonist-aluminum combination adjuvant to improve the quality and duration of the immune response. This SBIR contract was awarded under a solicitation that sought innovative...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $18.8 million cost-plus-fixed-fee definitive contract to Access To Advanced Health Institute (AAHI), a Seattle-based nonprofit biotech research organization, on September 21, 2018, with completion targeted for August 31, 2026. The contract supports advanced preclinical and clinical development of an intranasal recombinant amebiasis vaccine containing a liposomal adjuvant formulation incorporating toll-like receptor (TLR)...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order contract to Advanced Bioadjuvants, LLC, a self-certified small disadvantaged business. The contract is for license fees related to the Adjuplex trademark, patents, and trade secret manufacturing process, which NIAID will use to combine with human vaccines for clinical trials. The contract has a 12-month...
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $375,000 firm fixed price purchase order to Advanced Bioadjuvants, LLC of Omaha, Nebraska. The three-year contract, running from September 2021 through September 2024, provides a non-exclusive license to Advanced Bioadjuvants' Adjuplex adjuvant technology. This will allow the National Institute of Allergy and Infectious Diseases to manufacture cGMP grade...
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $780,764 firm fixed price purchase order contract to Access To Advanced Health Institute, doing business as Aahi, Idri, Infectious Disease Research Institute, located in Rockville, Maryland. Under the contract, Idri will provide investigational products GLA-SE adjuvant formulation and lyophilized ID93 from Idri for clinical trials funded by NIAID's Division of AIDS. As the prime contractor, Idri...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
- This firm fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), to Access To Advanced Health Institute (AAHI), doing business as Aahi, Idri, and Infectious Disease Research Institute. The $2,980 contract is for infectious disease research and development, specifically related to vaccine adjuvants. AAHI is a non-profit biotech research institute that combines academic...
- This is a $598,808 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Inimmune Corp. The contract is for research on adjuvant discovery for vaccines and for autoimmune and allergic diseases. Inimmune Corp is a biotechnology company with expertise in synthetic chemistry, drug formulation, and pharmaceutical manufacturing. They have received...